JP2009507777A - ＴＡＣＩ−Ｉｇ融合分子を用いたＢ細胞性腫瘍の処置方法 - Google Patents

ＴＡＣＩ−Ｉｇ融合分子を用いたＢ細胞性腫瘍の処置方法 Download PDF

Info

Publication number
JP2009507777A
JP2009507777A JP2008526212A JP2008526212A JP2009507777A JP 2009507777 A JP2009507777 A JP 2009507777A JP 2008526212 A JP2008526212 A JP 2008526212A JP 2008526212 A JP2008526212 A JP 2008526212A JP 2009507777 A JP2009507777 A JP 2009507777A
Authority
JP
Japan
Prior art keywords
taci
administered
dose
patient
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008526212A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009507777A5 (ru
Inventor
ブロリー，エルブ
ジーバース，エリック
イティエ，アルノー
ジェイ． バズビー，シャロン
エム． アンセル，スティーブン
エルストレム，ヤン
ネストロフ，イワン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Foundation for Medical Education and Research
Original Assignee
Mayo Foundation for Medical Education and Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation for Medical Education and Research filed Critical Mayo Foundation for Medical Education and Research
Publication of JP2009507777A publication Critical patent/JP2009507777A/ja
Publication of JP2009507777A5 publication Critical patent/JP2009507777A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2008526212A 2005-08-09 2006-08-09 ＴＡＣＩ−Ｉｇ融合分子を用いたＢ細胞性腫瘍の処置方法 Pending JP2009507777A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70691205P 2005-08-09 2005-08-09
PCT/US2006/031277 WO2007019575A2 (en) 2005-08-09 2006-08-09 Methods for treating b-cell malignancies using taci-ig fusion molecule

Publications (2)

Publication Number Publication Date
JP2009507777A true JP2009507777A (ja) 2009-02-26
JP2009507777A5 JP2009507777A5 (ru) 2009-09-03

Family

ID=37672215

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008526212A Pending JP2009507777A (ja) 2005-08-09 2006-08-09 ＴＡＣＩ−Ｉｇ融合分子を用いたＢ細胞性腫瘍の処置方法

Country Status (15)

Country Link
US (1) US7842292B2 (ru)
EP (1) EP1922080A2 (ru)
JP (1) JP2009507777A (ru)
KR (1) KR20080056714A (ru)
CN (1) CN101262876A (ru)
AR (1) AR059945A1 (ru)
AU (1) AU2006278229B2 (ru)
CA (1) CA2618765A1 (ru)
EA (1) EA016083B1 (ru)
IL (1) IL188403A (ru)
MX (1) MX2008001661A (ru)
NO (1) NO20081149L (ru)
UA (1) UA93516C2 (ru)
WO (1) WO2007019575A2 (ru)
ZA (1) ZA200801354B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11274140B2 (en) 2020-05-08 2022-03-15 Alpine Immune Sciences, Inc. APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US8808696B2 (en) 2005-08-09 2014-08-19 Ares Trading S.A. Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
JP2009507777A (ja) 2005-08-09 2009-02-26 ザイモジェネティクス，インコーポレイティド ＴＡＣＩ−Ｉｇ融合分子を用いたＢ細胞性腫瘍の処置方法
BRPI0711823A2 (pt) * 2006-05-15 2012-01-17 Ares Trading Sa métodos para tratamento de doenças auto-imunes com uma molécula de fusão taci-ig
PT2167038T (pt) * 2007-06-13 2018-06-01 Zymogenetics Inc Utilização de proteína de fusão taci-ig, tal como atacicept para o fabrico de um medicamento para tratar lúpus eritematoso
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
EP3211094A3 (en) 2009-09-03 2017-11-01 F. Hoffmann-La Roche AG Methods for treating, diagnosing, and monitoring rheumatoid arthritis
WO2012118750A2 (en) 2011-02-28 2012-09-07 Genentech, Inc. Biological markers and methods for predicting response to b-cell antagonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094852A2 (en) * 2001-05-24 2002-11-28 Zymogenetics, Inc. Taci-immunoglobulin fusion proteins

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
IE54046B1 (en) 1981-08-25 1989-05-24 Celltech Ltd Expression vectors
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4486533A (en) 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4977092A (en) 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4661454A (en) 1983-02-28 1987-04-28 Collaborative Research, Inc. GAL1 yeast promoter linked to non galactokinase gene
US5139936A (en) 1983-02-28 1992-08-18 Collaborative Research, Inc. Use of the GAL1 yeast promoter
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
CA1280080C (en) 1984-12-06 1991-02-12 Jacques Oberto Promoters for the expression of foreign genes in yeast, plasmids comprising them, and uses thereof for the production of polypeptides
US4751181A (en) 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5063154A (en) 1987-06-24 1991-11-05 Whitehead Institute For Biomedical Research Pheromone - inducible yeast promoter
US5637677A (en) 1987-07-16 1997-06-10 The Trustees Of The University Of Pennsylvania Biologically active compounds and methods of constructing and using the same
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
EP0325224B1 (en) 1988-01-22 1996-07-31 ZymoGenetics, Inc. Methods of producing secreted receptor analogs
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5162228A (en) 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
SG46445A1 (en) 1990-01-26 1998-02-20 Immunomedics Inc Vaccines against cancer and infectious diseases
ATE196310T1 (de) 1990-02-09 2000-09-15 Salk Inst For Biological Studi Retinoid-rezeptor-zusammensetzungen und verfahren
US5208146A (en) 1990-11-05 1993-05-04 The Regents Of The University Of California Murine monoclonal anti-idiotype antibodies
EP0749319A1 (en) 1992-09-14 1996-12-27 Pfizer Inc. Immortalized cells and uses therefor
WO1994009137A1 (en) 1992-10-15 1994-04-28 Genentech, Inc. Antibodies against type 2 tumor necrosis factor receptor
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5650550A (en) 1993-10-01 1997-07-22 The United States Of America As Represented By The Department Of Health And Human Services Mutant mice having a deficit of functional estrogen receptors
US5523227A (en) 1994-06-17 1996-06-04 The Board Of Trustees Of The Leland Stanford Junior Univ. DNA encoding calcium-signal modulating cyclophilin ligand
UA58489C2 (ru) 1994-12-15 2003-08-15 Йєда Рісерч Енд Дівелопмент Ко. Лтд Модуляторы функций рецепторов fas
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
DE19533447C1 (de) 1995-09-09 1996-12-05 Bbs Kraftfahrzeugtechnik Verfahren und Vorrichtung zum Befüllen eines Gießwerkzeugs mit einer Metallschmelze
US5716808A (en) 1995-11-09 1998-02-10 Zymogenetics, Inc. Genetic engineering of pichia methanolica
EP0889966A1 (en) 1995-11-09 1999-01-13 ZymoGenetics, Inc. Compositions and methods for producing heterologous polypeptides in pichia methanolica
DK0897390T3 (da) 1996-03-14 2004-03-08 Human Genome Sciences Inc Human tumornekrosefaktor-delta og -epsilon
AU708572B2 (en) 1996-07-17 1999-08-05 Zymogenetics Inc. Preparation of (pichia methanolica) auxotrophic mutants
IL128073A0 (en) 1996-07-17 1999-11-30 Zymogenetics Inc Transformation of pichia methanolica
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
ATE302272T1 (de) 1996-10-25 2005-09-15 Human Genome Sciences Inc Neutrokin alpha
US6689579B1 (en) 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
AU5705898A (en) 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (en) 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
JP2002504818A (ja) 1997-06-06 2002-02-12 リジェネロン ファーマシューティカルズ，インコーポレイテッド リガンドファミリーのｎｔｎ−２メンバー
AU7608898A (en) 1997-06-06 1998-12-21 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
WO1999004001A1 (en) 1997-07-21 1999-01-28 Zymogenetics, Inc. Tumor necrosis factor receptor ztnfr-5
US6015801A (en) 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
AU9376498A (en) 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
SK3542000A3 (en) 1997-09-12 2000-08-14 Apotech R & D Sa Nucleic acid coding ligand april, a vector, a host cell, method for preparing ligand april, a polypeptide of ligand april, a pharmaceutical composition and an antibody, and use thereof
EA200000311A1 (ru) 1997-09-12 2000-10-30 Апотек Р Энд Д Са Новый белок иммунной системы - кау
DE19831987A1 (de) 1998-07-16 2000-01-20 Bayer Ag Diphenylimidazoline
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
WO2000040714A2 (en) 1998-12-30 2000-07-13 Oligos Etc. Inc. Therapeutic phosphodiesterase inhibitors
DE60042617D1 (de) 1999-01-07 2009-09-03 Zymogenetics Inc Verfahren zur therapeutischen Verwendung von löslichen rezeptoren BR43X2
US20060067933A1 (en) 1999-01-07 2006-03-30 Gross Jane A Soluble receptor BR43x2 and methods of using
US7833529B1 (en) * 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
EP2298332B1 (en) 1999-01-25 2015-07-08 Biogen MA Inc. BAFF, inhibitors thereof and their use in the modulation of the B-cell response
EP1860190A3 (en) 1999-02-23 2008-03-12 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variants
EP1171148A2 (en) 1999-04-19 2002-01-16 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical desorders
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
PT1180159E (pt) 1999-05-28 2008-12-05 Targeted Genetics Corp Métodos e composições para abaixamento do nível de factor de necrose tumoral (tnf) nos distúrbios associados a tnf
CA2383154C (en) 1999-08-17 2013-04-30 Biogen, Inc. Baff receptor (bcma), an immunoregulatory agent
UA74798C2 (ru) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Способ лечения рака у млекопитающих с помощью полипептида, который препятствует взаимодействию между april и его рецепторами
IL150755A0 (en) * 2000-02-16 2003-02-12 Genentech Inc Uses of agonists and antagonists to modulate activity of tnf-related molecules
AU2006201471B2 (en) 2000-02-16 2009-07-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of TNF-related molecules
CN100390288C (zh) 2000-04-11 2008-05-28 杰南技术公司 多价抗体及其应用
SI1297013T1 (sl) * 2000-04-27 2007-06-30 Biogen Idec Inc Uporaba TACI kot protitumorskega sredstva
US20040013674A1 (en) 2001-04-27 2004-01-22 Christine Ambrose Taci as an anti-tumor agent
US20020086018A1 (en) 2000-05-12 2002-07-04 Theill Lars Eyde Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3, and TACI
ES2344679T3 (es) 2000-08-11 2010-09-03 Kyowa Hakko Kirin Co., Ltd. Polipeptidos que controlan el metabolismo del acido fosforico, el metabolismo del calcio, el metabolismo de la calcificacion y de la vitamina d y moleculas de adn que los codifican.
ES2329012T3 (es) 2000-11-07 2009-11-20 Zymogenetics, Inc. Receptor del factor de necrosis tumoral humano.
BR0211614A (pt) 2001-08-03 2006-10-31 Genentech Inc polipeptìdeo tacis e br3 e empregos dos mesmos
US20050163775A1 (en) 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
AU2004285455A1 (en) 2003-10-20 2005-05-12 Biogen Idec Ma Inc. Therapeutic regimens for BAFF antagonists
US8808696B2 (en) 2005-08-09 2014-08-19 Ares Trading S.A. Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
JP2009507777A (ja) 2005-08-09 2009-02-26 ザイモジェネティクス，インコーポレイティド ＴＡＣＩ−Ｉｇ融合分子を用いたＢ細胞性腫瘍の処置方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094852A2 (en) * 2001-05-24 2002-11-28 Zymogenetics, Inc. Taci-immunoglobulin fusion proteins

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11274140B2 (en) 2020-05-08 2022-03-15 Alpine Immune Sciences, Inc. APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof

Also Published As

Publication number Publication date
US7842292B2 (en) 2010-11-30
UA93516C2 (ru) 2011-02-25
AU2006278229B2 (en) 2011-10-27
AU2006278229A1 (en) 2007-02-15
CA2618765A1 (en) 2007-02-15
EA200800560A1 (ru) 2008-06-30
US20070071760A1 (en) 2007-03-29
IL188403A0 (en) 2008-08-07
IL188403A (en) 2011-06-30
WO2007019575A2 (en) 2007-02-15
NO20081149L (no) 2008-04-30
ZA200801354B (en) 2009-08-26
WO2007019575A3 (en) 2007-06-21
EA016083B1 (ru) 2012-02-28
EP1922080A2 (en) 2008-05-21
AR059945A1 (es) 2008-05-14
KR20080056714A (ko) 2008-06-23
CN101262876A (zh) 2008-09-10
MX2008001661A (es) 2008-04-07

Similar Documents

Publication Publication Date Title
US20220071959A1 (en) Combination therapies for the treatment of cancer
US7842292B2 (en) Methods for treating B-cell malignancies using a TACI-Ig fusion molecule
RU2750821C2 (ru) Препараты антител против her2 для подкожного введения
JP2013100313A (ja) Ｔａｃｉ融合分子を使用する自己免疫疾患を治療するための方法
JP2008502738A (ja) ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用
JP2014500278A (ja) 二重特異性ｓｃＦｖコンジュゲートの投薬量および投与
JP2017025086A (ja) 単独治療または他のがん治療と組み合わせたインターフェロンβの使用方法
US8808696B2 (en) Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
ES2681195T3 (es) Utilización de la proteína de fusión TACI-Ig, tal como atacicept, para la fabricación de un medicamento para el tratamiento de lupus eritematoso
Dreicer et al. A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer
JP2020517648A (ja) 抗ｃｄ５２抗体を用いて多発性硬化症を処置するための経路およびスケジュール
US11447778B2 (en) TNF-targeting aptamers and uses thereof for treatment or diagnosing TNF-related inflammatory diseases
CN117203242A (zh) 用TACI-Fc融合蛋白治疗干燥综合征的方法
JP2008509989A (ja) 乾癬症の治療におけるｔｎｆ結合タンパク質−１

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090715

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090715

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120113

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120918